Welcome Wondros Family and
Friends! We are beta testing and need
your help improving this product.
Share Feedback
Information provided by:
National Cancer Institute (NCI)
Last updated:
11/14/2022
Trial identifier:
NCT04530552
DisclaimerBrief summary:
This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testosterone can cause the growth of prostate cancer cells, and Apalutamide blocks the use of testosterone by the tumor cells. Giving low-dose apalutamide before prostate surgery may lead to lowered PSA levels in men with prostate cancer confined to the prostate gland.
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
UC San Diego Medical Center - Hillcrest
San Diego, California, United States, 92103
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, United States, 85719
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States, 21287
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
George Washington University Medical Center
Washington, District of Columbia, United States, 20037
NCI - Center for Cancer Research
Bethesda, Maryland, United States, 20892
Glossary term:
June 01, 2021
Glossary term:
August 31, 2024